Sawai Aims To Overcome US Slide
Japanese Firm Still Optimistic On Meeting Full-Year Forecasts
Sawai says it is still on track to meet its financial targets for the current financial year, despite a slump in US sales and profits.
You may also be interested in...
Sawai believes the Zembrace and Tosymra sumatriptan brands acquired by its US operation Upsher-Smith could within the next three years bring in more than $50m in annual sales.
In an exclusive interview, the president of Japan’s largest generics company relates his strategy for success, including internal expertise in intellectual property challenges and staying away from biosimilars. US acquisition Upsher-Smith will meanwhile provide the foundation for overseas growth.
Gene Techno Science and Kishi Kasei have struck a deal to jointly develop a Japanese aflibercept biosimilar rival to Eylea.